Sex-differences in the management and clinical outcome among patients with acute coronary syndrome

Yunliang Zou¹, Wenjian Zhu¹, Jing Zeng¹, Junyu Lin² and Siping Dai¹*

Abstract
Background: The current study was to compare the management and clinical outcome between women and men with acute coronary syndrome (ACS).
Method: This was a retrospective study. Patients with ACS presented to the emergency department were enrolled. Management and clinical outcomes (including mortality and acute decompensated heart failure [ADHF]) were compared between women and men.
Results: A total of 686 patients were included and women accounted for 38.5% (n = 264). Women were less likely to receive ticagrelor at the emergency department (18.2% vs 25.1%). Duration from arrival at the emergency department to undergo electrocardiogram was longer in women (7.5 min vs 5.3 min). The duration from symptom onset to undergo percutaneous coronary intervention was longer in women (14.4 h vs 7.2 h). After adjusting for covariates, odds ratio (OR) for cardiovascular mortality was 0.42 (95% confidence interval [CI] 0.37–1.02) and ADHF was 0.63 (95% CI 0.55–1.01) for women vs men. Socioeconomic status, duration from symptom onset to arrive at the emergency department, and management at the emergency department were the important factors contributing to the sex-differences in clinical outcome.
Conclusion: Among ACS patients undergoing PCI, there was no sex-difference in in-hospital clinical outcome after adjusting for covariates. Future studies are needed to evaluate whether improving management at the emergency department can improve clinical outcomes in women and men with ACS.

Keywords: Acute coronary syndrome, Sex, Clinical outcome, Mortality, Heart failure

Background
Despite advancement has been achieved in the last decade, acute coronary syndrome (ACS) remains a leading cause of morbidity and mortality worldwide [1–5]. The standardized incidence of ACS in Chinese adults was approximately 2185/million [6], and the mortality rate of ACS was approximately 6% [3], which was comparable to the developed countries [4, 5]. One recent report from the CCC-ACS project (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) indicated that compared to men, women with ACS were less likely to receive guideline-recommended therapy, which attributed to a higher mortality rate during hospitalization in women [7]. While this study did not account for the severity of coronary artery stenosis [7]. Indeed, results from prior study suggested that after adjusting for severity of coronary artery stenosis, there was no difference in 30-day mortality between women and men [8].
Sex-differences in ACS have been extensively evaluated [7, 9–14]. Nonetheless, most of prior studies were from western populations and data on Chinese ACS populations are remarkably limited. In addition, whether there are sex-differences in ACS management at the emergency department are unknown. Notably, effective management at the emergency department is essential to improve clinical outcomes for ACS patients [15, 16]. Considering the increasing prevalence of ACS in China and differences in clinical outcome between women and men [2, 3], it is clinically important to investigate whether there were sex-differences in management at the emergency department, and whether these differences would influence clinical outcome among ACS patients.

Herein, we performed a retrospective study to include ACS patients presented to the emergency department of our hospital. The management at the emergency and inpatient department and the clinical outcomes during hospitalization were evaluated in women and men.

Methods
Study participants
The current study was approved by the Institutional Review Board (IRB; No. 20190768A02) of the Third People’s Hospital of Huizhou. Since this was a retrospective study, the written consent form was waived by the IRB. All the experiment was conducted according to the Helsinki Declaration. Patients with ACS who were presented to the emergency department during January of 2019 to December of 2020 were screened. The included criteria were as follow: > 18 years old and underwent percutaneous coronary intervention (PCI) during hospitalization. The excluded criteria were as follow: patients who did not have cardiac troponin measurement at the emergency department; patients who died before undergoing PCI; patients who had critical complication including cardiogenic shock, refractory ventricular fibrillation or cardiac arrest at the emergency department, or who required ventilation and/or invasive hemodynamic support (e.g. intra-aortic balloon pump support) at the emergency department (Fig. 1).

Data collection
Data were extracted from the electronic health record of the emergency department and the inpatient healthcare system by two study investigators. Baseline data, including demographics, vital sign at the emergency department, socioeconomic status (education degree and insurance status), duration since symptom onset to the arrival of emergency department, approach to emergency department (emergency medical service, EMS), management at the emergency department, comorbid conditions (smoking, hypertension, dyslipidemia, diabetes mellitus [DM], atrial fibrillation, chronic kidney disease [CKD], chronic obstructive pulmonary disease [COPD], coronary heart disease [CHD], ischemic stroke, peripheral arterial disease, heart failure, and prior PCI), were collected. Laboratory included high sensitive cardiac
troponin-T (Hs-cTnT) and N-terminal pro-B type natriuretic peptide (NT-proBNP) at the emergency and inpatient department, glycated hemoglobin A1c (HbA1c), lipid panel, serum levels of blood urine nitrogen, creatinine, and C-reactive protein (CRP). Creatinine was used to calculate estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula. Procedural characteristics included duration since symptom onset to undergo PCI, arterial access site, number of coronary arteries ≥70% stenosis, lesion location and lesion length, type and number of stent implanted, TIMI flow grade of pre- and post-PCI, and antiplatelet loading at peri-PCI period. Medications used at the emergency and inpatient department were extracted from healthcare system.

Clinical outcome
Clinical outcome of current study included cardiovascular and non-cardiovascular mortality and acute decompenated heart failure (ADHF) during hospitalization. All the clinical outcomes were adjudicated by an independent cardiologist who did not participate in the current study.

Statistical analysis
Continuous variable with normal distribution was presented as mean ± standard deviation otherwise was presented as median (interquartile range). Categorical variables were presented as number and percentage. Participants were divided by sex and between-group differences were evaluated by Student t test or Mann–Whitney U test for continuous variables, and chi-squared test for categorical variables. Multivariable regression analysis was performed to evaluate the relationship between baseline characteristics and sex. Men was served as the reference group. Odds ratio (OR) and 95% confidence interval (CI) was reported. The incidence rate of clinical outcome was compared by sex. To examine the factors associated with the sex-difference in clinical outcome, sequential cumulative adjustment was performed as previously described [17]. Specifically, in the model 1, age was adjusted; in the model 2, age plus socioeconomic status was adjusted; in the model 3, factors in the model 1 and 2 and duration since symptom onset to emergency department and the approach to the emergency department was adjusted; in the model 4, factors in prior 3 models plus management at the emergency department was adjusted; in the model 5, factors in prior 4 models plus medical management in the inpatient department was adjusted; in the model 6, factors in prior 5 models plus procedural characteristics was adjusted. Odds ratio and 95% CI was reported. All the analyses were conducted using the SPSS 23.0 statistical software and a two-sided P value < 0.05 was considered as statistical significance.

Results
Comparisons of baseline characteristics by sex
A total of 686 patients were included and women accounted for 38.5% (n = 264; Fig. 1). Compared to men (Table 1), women were older, less likely to graduate from college and to have health insurance. In addition, they were more likely to present to the emergency department at a longer duration since symptom onset and less likely to use EMS to the emergency department. Women were less likely to smoke and have COPD and CHD, and they had a higher serum level of Hs-cTnT, NT-proBNP and CRP.

Comparisons of management by sex
Compared to men (Table 2), women were less likely to receive ticagrelor loading at the emergency department. The duration since arrival at emergency department to first electrocardiogram and Hs-cTnT test were longer in women, as was to receive cardiologist consultation. There were no differences in in-hospital medication use between women and men.

Comparisons of procedural characteristics by sex
The proportion of patients presented with ST-segment elevation myocardial infarction (STEMI), non-STEMI and unstable angina were comparable by sex (Table 3). The duration since symptom onset to undergo PCI was longer in women with STEMI. Women were less likely to use radial artery access. There were no sex-differences in antiplatelet loading at peri-PCI period, post-PCI TIMI flow grade, and the number and percentage of drug-eluting stent used.

Associations between baseline characteristics and sex
After multivariable regression analyses (Fig. 2), female sex was associated with lower odds of college graduation, having health insurance, using EMS, and receiving ticagrelor loading at the emergency department.

Comparison of clinical outcome by sex
Compared to men (Table 4), women had a higher incidence rate of cardiovascular mortality and ADHF during hospitalization, which together contributed to a higher composite clinical outcome. In the unadjusted model, the crude odds ratio for cardiovascular mortality was 2.57 (95% CI 1.09–6.27), ADHF was 1.65 (95% CI 1.02–2.66) and composite clinical outcome was 1.91 (95% CI 1.25–2.92), respectively.
As shown in Table 5, the OR reduced by 45%, 50%, 58%, 34%, 2% and 26% for cardiovascular mortality after sequential cumulative adjustment for age, socioeconomic status, duration since symptom onset to emergency department and the approach to emergency department, management at emergency department, medical management in inpatient department, and procedural characteristics, respectively. The OR reduced by 18%, 22%, 17%, 31%, 3% and 11% for ADHF after sequential cumulative adjustment for covariates of these six domains. These findings indicated that socioeconomic status, and duration since symptom onset to emergency department and the approach to emergency department were the two main factors contributing to the sex-difference in cardiovascular mortality, while socioeconomic status and management in the emergency department were the two main factors contributing to the sex-difference in ADHF.

Table 1  Baseline characteristics comparisons

| Variables                              | Men (n = 422) | Women (n = 264) | P-value |
|----------------------------------------|---------------|-----------------|---------|
| Age (years)                            | 57.3 ± 12.4   | 60.9 ± 13.8     | 0.03    |
| Education ≥ College, n (%)             | 124 (29.4)    | 62 (23.5)       | 0.01    |
| Health insurance, n (%)                | 387 (91.7)    | 226 (85.6)      | 0.02    |
| Duration since symptom onset to emergency department (h)* | 2.7 (0.9–5.2) | 3.6 (1.3–6.0) | 0.009   |
| Emergency medical service, n (%)       | 166 (39.6)    | 82 (31.1)       | 0.04    |
| Systolic blood pressure (mm Hg)        | 135 ± 14      | 137 ± 15        | 0.51    |
| Diastolic blood pressure (mm Hg)       | 79 ± 17       | 77 ± 16         | 0.38    |
| Heart rate (beat per minute)           | 97 ± 20       | 99 ± 19         | 0.17    |
| Smoking, n (%)                         | 228 (54.0)    | 15 (5.7)        | <0.001  |
| Hypertension, n (%)                    | 251 (59.5)    | 165 (62.5)      | 0.62    |
| Dyslipidemia, n (%)                    | 157 (37.2)    | 95 (36.0)       | 0.93    |
| Diabetes mellitus, n (%)               | 124 (29.4)    | 81 (30.7)       | 0.86    |
| Atrial fibrillation, n (%)             | 40 (9.5)      | 31 (11.7)       | 0.70    |
| COPD, n (%)                            | 69 (16.4)     | 5 (1.9)         | 0.006   |
| Chronic kidney disease, n (%)          | 78 (18.5)     | 58 (22.0)       | 0.09    |
| Coronary heart disease, n (%)          | 102 (24.2)    | 43 (16.3)       | 0.02    |
| Ischemic stroke, n (%)                 | 60 (14.2)     | 35 (13.3)       | 0.49    |
| PAD, n (%)                             | 52 (12.3)     | 38 (14.4)       | 0.18    |
| Heart failure, n (%)                   | 29 (6.9)      | 19 (7.2)        | 0.74    |
| Prior PCI, n (%)                       | 48 (11.4)     | 25 (9.5)        | 0.37    |
| Hs-cTnT at ED (pg/mL)*                 | 59 (33–267)   | 76 (44–304)     | 0.003   |
| NT-proBNP at ED (pg/mL)*               | 408 (178–836) | 521 (233–962)   | 0.009   |
| Hs-cTnT inpatient (pg/mL)*             | 86 (57–367)   | 112 (83–489)    | <0.001  |
| NT-proBNP inpatient (pg/mL)*           | 535 (260–1129)| 734 (495–1362) | <0.001  |
| HbA1c (%)                              | 5.9 ± 0.6     | 6.0 ± 0.6       | 0.81    |
| Total cholesterol (mmol/L)             | 5.0 ± 0.9     | 5.1 ± 1.0       | 0.36    |
| LDL-C (mmol/L)                         | 3.1 ± 0.5     | 3.1 ± 0.6       | 0.44    |
| HDL-C (mmol/L)                         | 1.1 ± 0.4     | 1.0 ± 0.4       | 0.70    |
| Triglyceride (mmol/L)*                 | 1.9 (0.7–2.8) | 1.9 (0.6–2.9)   | 0.15    |
| C-reactive protein (mg/dL)*            | 7.6 (3.5–20.4)| 12.3 (6.4–31.8)| <0.001  |
| Blood urine nitrogen (mg/dL)           | 7.1 ± 2.3     | 8.0 ± 2.6       | 0.82    |
| Creatinine (umol/L)                    | 80.4 ± 16.3   | 79.6 ± 17.9     | 0.35    |
| eGFR (ml/min/1.73m²)                   | 68.3 ± 14.5   | 64.2 ± 12.7     | 0.06    |

COPD, chronic obstructive pulmonary disease; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; Hs-cTnT, high sensitivity cardiac troponin-T; NT-proBNP, N-terminal pro B-type natriuretic peptide; ED, emergency department; HbA1c, glycated hemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate

*Presented as median (interquartile range)
Discussion

To the best of our knowledge, the current study should be the first few studies to evaluate the sex-differences in the management at emergency department and in-hospital clinical outcome in Chinese ACS patients. There are three main findings of the current study. First, compared to men, women received less effective and efficient treatment at the emergency department, which in turn might contribute to a worse prognosis in women. Second, the higher in-hospital rate of cardiovascular mortality and ADHF in women was disappeared after adjusting for covariates. Third, sequential cumulative regression analyses indicated that socioeconomic status, duration since symptom onset to emergency department and the approach to the emergency department, and management at emergency department were the three main factors contributing to the worse prognosis in women.

Acute coronary syndrome causes substantial health and economic loss in China and worldwide [3–5]. It is well-recognized that immediate and effective management are essential to improve clinical outcome for ACS patients. With advancement in therapy, the prognosis of ACS patient is improved in the last two decades. Nevertheless, there were substantial sex-differences in the improvement. For example, Raphael et al. reported that among individuals undergoing PCI, women had a higher mortality rate than men [10]. Using data from 21 randomized PCI trials, Kosmidou et al. reported that female sex was an independent predictor of major adverse cardiovascular events [18]. One recent study from Chinese ACS populations undergoing PCI indicated that women had a higher in-hospital mortality rate than men [7]. Using data from China Patient-Centered Evaluative Assessment of Cardiac Events (PEACE), Dreyer et al. reported that women in China had higher crude rates of all-cause and cardiovascular mortality even after adjusting for multiple covariates [9]. One recent meta-analysis showed that P2Y12 inhibitor monotherapy lowered the risk of the primary ischemic endpoint in women but not in men [19], suggesting the sex-specific effect of antiplatelet therapy in patients with revascularization. Results of the current study showed that women had a higher crude risk of cardiovascular mortality and ADHF than men. However, after adjusting for other covariates, there was no sex-differences in clinical outcomes, suggesting that female sex per se was not an independent risk factor for worse prognosis.

Extending from prior reports, the current study showed that women received less optimal treatment at the emergency department. In specific, compared to men, it took

### Table 2 Comparisons of management in emergency and inpatient department by sex

| Variables | Men (n = 422) | Women (n = 264) | P-value |
|-----------|--------------|----------------|---------|
| **Emergency department** | | | |
| Aspirin loading, n (%) | 326 (77.3) | 191 (72.3) | 0.18 |
| Clopidogrel loading, n (%) | 187 (44.3) | 127 (48.1) | 0.69 |
| Ticagrelor loading, n (%) | 106 (25.1) | 48 (18.2) | 0.03 |
| Nitroglycerin IV, n (%) | 126 (29.9) | 72 (27.3) | 0.24 |
| Morphine IV, n (%) | 30 (7.1) | 25 (9.5) | 0.11 |
| Duration since arrived at ED to first ECG test (min)* | 5.7 (3.1–10.2) | 7.5 (4.7–12.5) | 0.006 |
| Duration since arrival at ED to first Hs-cTNT test (min)* | 7.0 (4.9–13.5) | 9.1 (5.6–15.3) | 0.01 |
| Duration since arrival at ED to Cardiologist consultation (min)* | 15.3 (8.5–19.1) | 17.8 (9.6–20.7) | 0.03 |
| **Inpatient department** | | | |
| Aspirin, n (%) | 422 (100) | 264 (100) | 0.99 |
| Clopidogrel, n (%) | 367 (87.0) | 225 (85.2) | 0.86 |
| Ticagrelor, n (%) | 50 (11.8) | 25 (9.5) | 0.59 |
| Statins, n (%) | 412 (97.6) | 253 (95.8) | 0.72 |
| Betablocker, n (%) | 336 (79.6) | 205 (77.7) | 0.48 |
| RASi, n (%) | 252 (59.7) | 138 (52.3) | 0.08 |
| PPI, n (%) | 129 (30.6) | 79 (29.9) | 0.70 |
| Antidiabetic, n (%) | 113 (26.8) | 73 (27.7) | 0.83 |
| Anticoagulant, n (%) | 25 (5.9) | 17 (6.4) | 0.64 |
| Oxygen supplement, n (%) | 73 (17.3) | 58 (22.0) | 0.06 |

IV, intravenous; ED, emergency department; ECG, electrocardiogram; Hs-cTNT, high sensitivity cardiac troponin-T; RASi, renin-angiotensin-system inhibitor; PPI, proton pump inhibitor

*Presented as median (interquartile range)
a longer duration for women to have electrocardiogram and Hs-cTnT test, which in turn might lead to delayed cardiologist consultation and a longer waiting duration to undergo PCI. The reason to explain the delay to undergo electrocardiogram and Hs-cTnT test in women might be partly due to their unspecific symptoms. Indeed, one recent meta-analysis has shown that compared to men, women with ACS were less likely to present with chest pain and diaphoresis, while they were more likely to present with pain between the shoulder blades or with gastrointestinal symptom [20]. Continued education and flowchart highlighting the unspecific symptoms of ACS women at the emergency department may help avoid the delay of performing electrocardiogram and Hs-cTnT test for ACS women. In addition, women were less likely to receive potent antiplatelet drug (ticagrelor) loading at the emergency department. These differences together might contribute to the worse prognosis in women. Indeed, immediate cardiologist consultation and potent antiplatelet drug loading are two essential factors associated with the prognosis for ACS patients [5, 21]. Interestingly and importantly, one recent meta-analysis has evaluated whether there was difference in ischemic events between P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularization [19]. The results suggested that monotherapy was associated with lower risk of ischemic events in women but not in men, suggesting that monotherapy might be sufficient for women but not for men. Biological differences in response to antiplatelet therapy by sex might partly explain these observations. However, due to the subgroup analysis, these findings can only be used for hypothesis generation and should be confirmed in clinical trial.

Factors from different domains have been ascribed to explain the observed sex-differences in clinical outcome. For example, Ho et al. reported that the sex-differences in in-hospital mortality were mainly due to worse clinical profiles and fewer evidence-based treatments for ACS women [7]. Cenko et al. reported that delayed hospitalization was independently associated

| Variables                                | Men (n = 422) | Women (n = 264) | P-value |
|------------------------------------------|--------------|----------------|---------|
| ST-segment elevation MI, n (%)           | 172 (40.8)   | 111 (42.0)     | 0.46    |
| Non-ST-segment elevation MI, n (%)       | 156 (37.0)   | 94 (35.6)      | 0.60    |
| Unstable angina, n (%)                   | 94 (22.2)    | 59 (22.3)      | 0.89    |
| Duration since symptom onset to undergo PCI (hour)* | 7.2 (4.8–55.2) | 14.4 (9.6–60) | 0.04    |
| Radial artery access, n (%)              | 395 (93.6)   | 223 (84.5)     | 0.03    |
| Number of coronary arteries ≥ 70% stenosis | 1.7 ± 0.6   | 1.8 ± 0.6      | 0.58    |
| Lesion length, mm                        | 25.6 ± 6.1   | 24.8 ± 5.8     | 0.31    |
| Lesion locations                         |              |                |         |
| Left main, n (%)                         | 83 (19.7)    | 56 (21.2)      | 0.62    |
| LAD, n (%)                               | 186 (44.1)   | 120 (45.5)     | 0.44    |
| LCX, n (%)                               | 178 (42.2)   | 115 (43.6)     | 0.39    |
| RCA, n (%)                               | 209 (49.5)   | 138 (52.3)     | 0.08    |
| Pre-PCI TIMI flow                        |              |                |         |
| Grade 3                                  | 0            | 0              | –       |
| Grade 2                                  | 59 (14.0)    | 43 (16.3)      | 0.26    |
| Grade 1                                  | 203 (48.1)   | 123 (46.6)     | 0.15    |
| Grade 0                                  | 160 (37.9)   | 98 (37.1)      | 0.93    |
| Post-PCI TIMI flow                       |              |                |         |
| Grade 3                                  | 403 (95.5)   | 243 (92.0)     | 0.07    |
| Grade 2                                  | 19 (4.5)     | 21 (8.0)       | 0.36    |
| Grade 1                                  | 0            | 0              | –       |
| Grade 0                                  | 0            | 0              | –       |
| Oral antiplatelet loading at peri-PCI period, n (%) | 74 (17.5) | 43 (16.3) | 0.68 |
| Glycoprotein IIb/IIIa inhibitor, n (%)   | 28 (6.6)     | 19 (7.2)       | 0.23    |
| Number of stents implanted               | 1.8 ± 0.7    | 1.9 ± 0.7      | 0.91    |
| Drug-eluting stent, n (%)                | 418 (99.1)   | 260 (98.5)     | 0.83    |

PCI, percutaneous coronary intervention; MI, myocardial infarction; LAD, left anterior descending; LCX, left circumflex; RCA, right coronary artery

*Presented as median (interquartile range) for STEMI patients only
The higher mortality rate in women undergoing PCI were due to their older age and greater comorbid burden [10]. Batchelor et al. reported that women experienced a higher risk of recurrent ischemic events after PCI treatment, which were primarily due to their lower socioeconomic status [23]. Leveraging data from the Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) cohort, Hess et al. reported that differences in demographic, clinical, and treatment profiles explained the higher rate of major adverse cardiac event in women [24]. We observed that socioeconomic status, and duration since symptom onset to emergency department and the approach to emergency department were the two main factors associated with sex-differences in cardiovascular mortality. In specific, women had a lower literacy and were less likely to have health insurance, which might be associated with the delay to emergency department and lower use of EMS. Indeed, low socioeconomic status is an independent risk factor of poor prognosis, and the reasons to explain these observations which included low health literacy, poor health insurance, nonadherence to medication use, lack of access to healthcare, insufficient family support among others [25, 26]. While for ADHF, socioeconomic status and management at emergency department were the two main factors explaining the observed sex-differences. Indeed, the delay for first electrocardiogram and Hs-cTNT test and cardiologist consultation might be associated with delay of undergoing PCI, which in turn caused more severe myocardial injury. Women had a higher serum level of Hs-cTNT, suggesting a greater myocardial necrosis and a higher risk of developing HF [27]. Higher level of NT-proBNP level, a parameter of cardiac stress, portends an increased risk of HF [28, 29]. Taken together, prior and the current studies suggested that the mechanisms underlying sex-difference in clinical outcome among ACS patients undergoing PCI are complex and multifactorial. Improvement of
management at the emergency department for women may be beneficial to reduce the sex-differences in clinical outcome.

**Limitations**

There are some limitations of the current study. First, this was a retrospective study and findings from the current study should not be drawn for any causal relationship. Second, although we had extensively adjusted for covariates, unmeasured and unknown covariates (e.g. estrogen and menopausal status) might influence the relationship between sex and clinical outcomes. Third, this was a single center study from Chinese populations. Large sample size study from multiple center and different population groups are needed to corroborate the current findings. Fourth, it is unknown whether the sex-differences in in-hospital clinical outcome would extend to a long-term follow-up. Further study with long-term follow-up is warranted.

**Conclusion**

In conclusion, findings of the current study suggest that among ACS patients undergoing PCI, there was no sex-difference in in-hospital clinical outcome after adjusting for covariates. Future studies are needed to evaluate whether improving management at the emergency department can improve clinical outcomes in women and men with ACS.

**Acknowledgements**

We appreciate very much for all the healthcare staff who assisted in the current study.

**Authors’ contributions**

YLZ and SPD conceived the study, participated in the design and drafted the manuscript; YLZ performed the statistical analyses; YLZ, WJZ, JZ, JYL and SPD collected the data. All authors read and approved the final manuscript.

**Funding**

None.

**Availability of data and materials**

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

The study design was approved by the Institutional Review Board (IRB) of The Third People's Hospital of Huizhou, Huizhou, Guangdong, China. This was a retrospective study and informed consent was waived by the Institutional Review Board of The Third People’s Hospital of Huizhou. All the experiment was conducted according to the Helsinki Declaration.

**Consent for publication**

Not Applicable.

**Competing interests**

None.

**Author details**

1. Department of Emergency, The Third People’s Hospital of Huizhou, The Affiliated Hospital of Guangzhou Medical University, Huizhou, Guangdong, China.
2. Department of Cardiology, The Third People’s Hospital of Huizhou, The Affiliated Hospital of Guangzhou Medical University, Huizhou, Guangdong, China.

**Received**: 10 June 2021 **Accepted**: 7 December 2021 **Published online**: 20 December 2021

**References**

1. Chinese guidelines for the prevention of cardiovascular diseases (2017). Zhonghua xin xue guan bing za zhi. 2018;46(10–25).
2. Du X, Patel A, Anderson CS, Dong J, Ma C. Epidemiology of cardiovascular disease in China and opportunities for improvement: JACC international. J Am Coll Cardiol. 2019;73:3135–47.
3. Ma LY, Chen WW, Gao RL, Liu LS, Zhu ML, Wang YJ, Wu ZS, Li HJ, Gu DF, Yang YF, Zheng Z, Hu SS. China cardiovascular diseases report 2018: an updated summary. J Genet Cardiol. 2020;17:1–8.
4. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, D’Ossoule L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwam TN, Lackland DT, Lewis TT, Lichtman JH, Lomengecker C, Tu, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson LP, Satou GM, Schroeder EB, Shay SH, Shaw CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141:e139–596.
5. Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bharat DL, Dentale P, Donabantu M, Edwardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehlli J, Meliga E, Merely B, Mueller C, Roffi M, Rutten FH, Simbong D, Sontis GCM. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020.
6. Gao YL, Su JT, Wei ZG, Liu JL, Wang J. Characteristics of out-of-hospital acute coronary heart disease deaths of Beijing permanent residents at
the age of 25 or more from 2007 to 2009. Zhonghua Xin Xue Guan Bing Za Zhi. 2012;40:199–203.

7. Hao Y, Liu J, Liu J, Yang N, Smith SC Jr, Hvo Y, Fonarow GC, Ge J, Taubert KA, Morgan L, Zhou M, Xing Y, Ma CS, Han Y, Zhao D. Sex differences in in-hospital management and outcomes of patients with acute coronary syndrome. Circulation. 2019;139:1776–85.

8. Berger JS, Elliott L, Gallup D, Roe M, Granger CB, Armstrong PW, Simes RJ, White HD, Van der Werf F, Topol EJ, Hochman JS, Newby LB, Harrington RA, Califf RM, Becker RC, Douglas PS. Sex differences in mortality following acute coronary syndromes. JAMA. 2009;302:874–82.

9. Dreyer RP, Zheng X, Xu X, Liu S, Li J, Deng Q, Du X, Li X, Zhang H, Masoudi FA, Spertus JA, Krumholz HM, Jiang L. Sex differences in health outcomes at one year following acute myocardial infarction: a report from the China Patient-Centered Evaluative Assessment of Cardiac Events prospective acute myocardial infarction study. Eur Heart J. Acute Cardiac Care. 2019;8:273–81.

10. Raphael CE, Singh M, Bell M, Crusan D, Lennon RJ, Lerman A, Prasad A, Rihal CS, Gersh BJ, Galulat R. Sex differences in long-term cause-specific mortality after percutaneous coronary intervention: temporal trends and mechanisms. Circ Cardiovasc Interv. 2018;11:e006062.

11. Peters SAE, Colantonio LD, Zhao H, Bittner V, Dai Y, Yarkhou ME, Mondia KL, Safford MM, Munter P, Woodward M. Sex differences in high-intensity statin use following myocardial infarction in the United States. J Am Coll Cardiol. 2018;72:2729–37.

12. Kunadian V, Qiu W, Lagraviste B, Johnston N, Sinclair H, Tan Y, Ludman T, James S, Singh M, Bell M, Crusan D, Lennon RJ, Lerman A, Prasad A, Raphael CE, Sarno G. Gender differences in outcomes and predictors of all-cause mortality after percutaneous coronary intervention (Data from United Kingdom and Sweden). Am J Cardiol. 2017;119:210–6.

13. Mefford MT, Li BH, Qian L, Reading SR, Harrison TN, Scott RD, Cavendish GW. Long-term outcomes in women and men following percutaneous coronary intervention. J Am Coll Cardiol. 2016;63:471–80.

14. Pagidipati NJ, Peterson ED. Acute coronary syndromes in women and men. Nat Rev Cardiol. 2016;13:471–80.

15. Dai S, Huang B, Zou Y, Guo J, Liu Z, Pi D, Qiu Y, Xiao C. The HEART score is useful to predict cardiovascular risks and reduces unnecessary cardiac imaging in low-risk patients with acute chest pain. Medicine. 2018;97:e10844.

16. Tomaszewski CA, Nester D, Shah KH, Sudhir A, Brown MD. Clinical policy: critical issues in the evaluation and management of emergency department patients with suspected non-ST-elevation acute coronary syndromes. Ann Emerg Med. 2018;72:e65–106.

17. Cai A, Dillon C, Hillegas WB, Bittner VA, Perry GJ, Brott BC, Bittner VA, Perry GJ, Brott BC. Sex differences in PCI-related complications: insights from the PLATINUM diversity and PROMUS element plus post-approval study pooled analysis. JAMA Cardiol. 2017;2:1303–13.

18. Hess CN, McCoy LA, Duggirala HJ, Tavris DR, O’Callaghan K, Douglas PS, Peterson ED, Wang TY. Sex-based differences in outcomes after percutaneous coronary intervention for acute myocardial infarction: a report from TRANSLATE-ACTS. J Am Heart Assoc. 2014;3:e000523.

19. Schultz WM, Kelli HM, Lisko JC, Varghese T, Shen J, Sandesara P, Qayunam AA, Treibich HA, Galati M, Harold GD, Mieres JH, Ferdinand KC, Mensah GA, Slinger LS. Socioeconomic status and cardiovascular outcomes: challenges and interventions. Circulation. 2018;137:2166–78.

20. Rosengren A, Smyth A, Ranganjaran S, Ramasundararaghette C, Bangdiwala SI, Alhábib KF, Avezum A, Bengtsson Boström K, Chifamba J, Gulec S, Gupta R, Iqubmbor EU, Iqubr R, Ismail N, Joseph P, Kaur M, Khatri R, Kruger JM, Lamelas P, Larsa F, Lear SA, Li W, Wang C, Quan D, Wang Y, Lopez-Jaramillo P, Mohammadfar N, Mohan M, Vony PK, Porier P, Sirilatha S, Szuba A, Teo K, Wielgosz A, Yeates KE, Yusof K, Yusuf R, Yusufali AH, Attaei MW, McKee M, Yusuf S. Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the prospective urban rural epidemiologic (PURE) study. Lancet Glob Health. 2019;7:e748–60.

21. Yan I, Böscher CS, Neumann JT, Sprünker NA, Makovacova N, Kontto J, Kualsmaa K, Salomaa V, Magnussen C, Iacoviello L, Di Castelnuovo A, Costanzo S, Linneberg A, Söderberg S, Zeller T, Ojeda-Echevarría FM, Blankenberg S, Westermann D. High-sensitivity cardiac troponin I levels and prediction of heart failure: results from the BiomarCaRE consortium. JACC Heart Fail. 2020;8:401–11.

22. Volpe M, Rubatto S, Burnett J Jr. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J. 2014;35:419–25.

23. Ibrahim NE, Burnett JC Jr, Butler J, Camacho A, Felker GM, Fiuzat M, James S, Sarno G. Gender differences in outcomes and predictors of heart failure: results from the BiomarCaRE consortium. JACC Heart Fail. 2020;8:547–58.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.